1. Home
  2. SND vs NGEN Comparison

SND vs NGEN Comparison

Compare SND & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smart Sand Inc.

SND

Smart Sand Inc.

HOLD

Current Price

$4.66

Market Cap

204.2M

Sector

Industrials

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$1.91

Market Cap

197.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SND
NGEN
Founded
2011
2017
Country
United States
Canada
Employees
318
9
Industry
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
204.2M
197.5M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
SND
NGEN
Price
$4.66
$1.91
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
357.6K
920.0K
Earning Date
05-05-2026
04-02-2026
Dividend Yield
2.81%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$330,153,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.03
N/A
52 Week Low
$1.76
$1.70
52 Week High
$5.92
$5.93

Technical Indicators

Market Signals
Indicator
SND
NGEN
Relative Strength Index (RSI) 43.08 35.25
Support Level $4.62 $1.70
Resistance Level $5.75 $4.44
Average True Range (ATR) 0.31 0.18
MACD -0.07 0.07
Stochastic Oscillator 11.42 31.78

Price Performance

Historical Comparison
SND
NGEN

About SND Smart Sand Inc.

Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics. The company has two reportable segments, Sand and SmartSystems. It derives maximum revenue from Sand segment, which includes both frac sand sales and IPS sales. Geographically, the company derives maximum revenue from United States, followed by Canada.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: